| |
| |
|
| Insider
Information: |
Zanganeh Maky |
| Relationship: |
Chief Executive Office... |
| City: |
Sunnyvale |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
1,125,725 |
|
|
Indirect Shares
|
198,074 |
|
|
| Direct
Value |
$7,036,769 |
|
|
|
Indirect Value
|
$1,378,458 |
|
|
| Total
Shares |
1,323,799 |
|
|
| Total
Value |
$8,415,227 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
11
|
0
|
|
Stock
price went up :
|
10
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
10.0
|
0.0
|
| Percentage
Gain/Loss : |
 62.6%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pharmacyclics Inc |
PCYC |
Chief Operating Officer |
2015-05-26 |
0 |
2015-05-26 |
0 |
Premium* |
|
|
Pulse Biosciences, Inc. |
PLSE |
Director |
2023-11-13 |
604,911 |
2023-11-13 |
148,074 |
Premium* |
|
|
Summit Therapeutics Inc |
SMMT |
Chief Executive Office... |
2024-03-27 |
520,814 |
2024-03-27 |
50,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SMMT |
Summit Therapeutics Inc |
Co-CEO & President |
• • – |
2023-03-08 |
4/A |
B |
$1.05 |
$24,703,396 |
I/I |
23,527,044 |
9,884,095 |
2.66 |
- |
|
| SMMT |
Summit Therapeutics Inc |
Co-Chief Executive Officer |
• • – |
2023-03-08 |
4 |
B |
$1.05 |
$16,772,430 |
D/D |
15,973,743 |
23,395,269 |
2.81 |
% |
|
| SMMT |
Summit Therapeutics Inc |
Co-Chief Executive Officer |
• • – |
2023-03-08 |
4 |
B |
$1.05 |
$7,930,966 |
I/I |
7,553,301 |
9,884,095 |
2.66 |
% |
|
| SMMT |
Summit Therapeutics Inc |
Co-CEO & President |
• • – |
2022-08-16 |
4 |
B |
$0.97 |
$5,455,961 |
I/I |
5,624,702 |
3,135,466 |
2.66 |
% |
|
| SMMT |
Summit Therapeutics Inc |
Chief Executive Officer |
• • – |
2023-12-11 |
4 |
OE |
$1.44 |
$705,332 |
D/D |
489,814 |
489,814 |
0 |
- |
|
| SMMT |
Summit Therapeutics Inc |
Chief Operating Officer |
• • – |
2021-05-12 |
4 |
B |
$5.24 |
$2,038,763 |
I/I |
389,077 |
2,643,319 |
2.66 |
% |
|
| SMMT |
Summit Therapeutics Inc |
Co-CEO & President |
• • – |
2022-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
373,857 |
10,930,849 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2015-05-26 |
4 |
D |
$261.25 |
$91,775,296 |
D/D |
(351,293) |
0 |
0 |
- |
|
| SMMT |
Summit Therapeutics Inc |
Chief Executive Officer |
• • – |
2023-12-11 |
4 |
OE |
$1.58 |
$498,776 |
I/I |
315,681 |
24,889,479 |
0 |
- |
|
| SMMT |
Summit Therapeutics Inc |
Co-CEO & President |
• • – |
2022-08-16 |
4 |
B |
$0.97 |
$178,897 |
D/D |
184,430 |
359,969 |
2.81 |
% |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2015-03-12 |
4/A |
OE |
$0.75 |
$180,279 |
D/D |
140,719 |
366,031 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2015-03-12 |
4 |
OE |
$0.75 |
$69,375 |
D/D |
92,500 |
317,812 |
0 |
- |
|
| PLSE |
Pulse Biosciences, Inc. |
Director |
– • – |
2022-06-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
86,668 |
442,168 |
0 |
- |
|
| PLSE |
Pulse Biosciences, Inc. |
Director |
• • – |
2023-06-09 |
4/A |
OE |
$2.05 |
$177,669 |
D/D |
86,668 |
528,836 |
0 |
- |
|
| PLSE |
Pulse Biosciences, Inc. |
Director |
• • – |
2023-06-09 |
4 |
OE |
$2.05 |
$177,669 |
D/D |
86,668 |
791,915 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2015-05-26 |
4 |
D |
$261.25 |
$20,113,115 |
I/I |
(76,988) |
0 |
0 |
- |
|
| PLSE |
Pulse Biosciences, Inc. |
Director |
• • – |
2023-11-13 |
4 |
OE |
$2.14 |
$162,801 |
D/D |
76,075 |
604,911 |
0 |
- |
|
| SMMT |
Summit Therapeutics Inc |
Chief Executive Officer |
• • – |
2024-03-27 |
4 |
B |
$3.71 |
$201,874 |
I/I |
54,321 |
50,000 |
2.66 |
% |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2015-03-12 |
4 |
OE |
$2.30 |
$110,904 |
D/D |
48,219 |
366,031 |
0 |
- |
|
| PLSE |
Pulse Biosciences, Inc. |
Director |
– • – |
2017-05-09 |
4 |
B |
$20.16 |
$680,500 |
I/I |
33,760 |
80,474 |
2.1 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2015-03-11 |
4 |
OE |
$7.19 |
$215,700 |
D/D |
30,000 |
255,312 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2015-03-11 |
4 |
S |
$254.11 |
$7,623,444 |
D/D |
(30,000) |
225,312 |
0 |
- |
|
| SMMT |
Summit Therapeutics Inc |
Chief Executive Officer |
• • – |
2024-03-26 |
4 |
B |
$3.75 |
$112,500 |
I/I |
30,000 |
30,000 |
2.66 |
% |
|
| SMMT |
Summit Therapeutics Inc |
Chief Executive Officer |
• • – |
2024-03-27 |
4 |
B |
$3.72 |
$96,720 |
D/D |
26,000 |
520,814 |
2.81 |
% |
|
| PCYC |
Pharmacyclics Inc |
Chief Operating Officer |
• – – |
2014-11-10 |
4 |
S |
$133.50 |
$3,078,027 |
D/D |
(23,000) |
210,312 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
